PacBio (NASDAQ: PACB) introduced that Novogene is utilizing its Revio long-read sequencing system to increase capabilities at its new lab in Munich, Germany. The Revio system’s elevated accuracy and throughput are designed to allow Novogene’s prospects to scale genomic analysis throughout uncommon illnesses, most cancers, microbes, and agriculture cost-effectively.
Novogene anticipates excessive demand for Revio from prospects in uncommon illness and most cancers analysis, in addition to in microbial and agrigenomics fields. The system’s skill to uncover advanced repetitive areas, structural variants, and novel isoforms makes it invaluable for superior genomic research. Novogene plans to combine extra automation into Revio’s workflows to extend effectivity and accessibility for a wider vary of shoppers.
PacBio (NASDAQ: PACB) ha annunciato che Novogene sta utilizzando il suo sistema di sequenziamento a lungo learn Revio per ampliare le capacità nel suo nuovo laboratorio a Monaco, in Germania. L’aumento della precisione e della capacità del sistema Revio è progettato per consentire ai clienti di Novogene di scalare la ricerca genomica su malattie uncommon, cancro, microbi e agricoltura in modo economico.
Novogene prevede una domanda elevata per Revio da parte dei clienti nella ricerca su malattie uncommon e cancro, così come nei campi microbici e di agrigenomica. La capacità del sistema di scoprire aree ripetitive complesse, varianti strutturali e nuovi isoformi lo rende prezioso per studi genomici avanzati. Novogene prevede di integrare maggiore automazione nei flussi di lavoro di Revio per aumentare l’efficienza e l’accessibilità a una gamma più ampia di clienti.
PacBio (NASDAQ: PACB) anunció que Novogene está utilizando su sistema de secuenciación de lectura larga Revio para ampliar las capacidades en su nuevo laboratorio en Múnich, Alemania. El aumento de la precisión y capacidad del sistema Revio está diseñado para permitir a los clientes de Novogene escalar la investigación genómica en enfermedades raras, cáncer, microbios y agricultura de manera rentable.
Novogene anticipa alta demanda de Revio por parte de los clientes en investigación sobre enfermedades raras y cáncer, así como en los campos de microbiología y agrigenómica. La capacidad del sistema para descubrir regiones repetitivas complejas, variantes estructurales y nuevos isoformas lo hace valioso para estudios genómicos avanzados. Novogene planea integrar más automatización en los flujos de trabajo de Revio para aumentar la eficiencia y accesibilidad a una gama más amplia de clientes.
PacBio (NASDAQ: PACB)는 Novogene이 독일 뮌헨에 있는 새로운 연구소에서 Revio 장기 읽기 시퀀싱 시스템을 사용하여 능력을 확장하고 있다고 발표했습니다. Revio 시스템의 향상된 정확도와 처리량은 Novogene의 고객이 희귀 질병, 암, 미생물 및 농업에 걸친 유전체 연구를 비용 효율적으로 확장할 수 있도록 설계되었습니다.
Novogene는 희귀 질병 및 암 연구, 그 뿐만 아니라 미생물학 및 농업 유전체학 분야에서 Revio에 대한 높은 수요를 예상하고 있습니다. 복잡한 반복 영역, 구조적 변이 및 새로운 아이소폼을 밝혀낼 수 있는 이 시스템은 고급 유전체 연구에 매우 유용합니다. Novogene는 Revio의 작업 흐름에 더 많은 자동화를 통합하여 더 많은 고객에게 효율성과 접근성을 높일 계획입니다.
PacBio (NASDAQ: PACB) a annoncé que Novogene utilise son système de séquençage à lengthy rayon Revio pour élargir ses capacités dans son nouveau laboratoire à Munich, en Allemagne. L’augmentation de la précision et du débit du système Revio est conçue pour permettre aux shoppers de Novogene d’évoluer dans la recherche génomique sur les maladies rares, le most cancers, les microbes et l’agriculture de manière rentable.
Novogene anticipe une forte demande pour Revio de la half des shoppers dans la recherche sur les maladies rares et le most cancers, ainsi que dans les domaines de la microbiologie et de l’agri-génomique. La capacité du système à découvrir des régions répétitives complexes, des variantes structurelles et de nouveaux isoformes en fait un outil précieux pour des études génomiques avancées. Novogene prévoit d’intégrer davantage d’automatisation dans les flux de travail de Revio pour augmenter l’efficacité et l’accessibilité pour un plus giant éventail de shoppers.
PacBio (NASDAQ: PACB) gab bekannt, dass Novogene sein Revio-Langsequenzierungssystem nutzt, um die Möglichkeiten in seinem neuen Labor in München, Deutschland, zu erweitern. Die erhöhte Genauigkeit und Durchsatz des Revio-Programs sind darauf ausgelegt, es Novogene-Kunden zu ermöglichen, genomische Forschung in seltenen Krankheiten, Krebs, Mikroben und Landwirtschaft kosteneffizient zu skalieren.
Novogene erwartet eine hohe Nachfrage nach Revio von Kunden in der Forschung zu seltenen Krankheiten und Krebs sowie in den Bereichen mikrobielle und Agrar-Genomik. Die Fähigkeit des Programs, komplexe wiederholte Regionen, strukturelle Varianten und neue Isoformen aufzudecken, macht es für fortgeschrittene genomische Studien wertvoll. Novogene plant, mehr Automatisierung in die Arbeitsabläufe von Revio zu integrieren, um die Effizienz und Zugänglichkeit für eine breitere Kundenbasis zu erhöhen.
Optimistic
- Growth of Novogene’s capabilities with PacBio’s Revio system
- Potential enhance in demand for PacBio’s know-how in numerous analysis fields
- Revio’s skill to uncover advanced genomic areas missed by different strategies
- Plans for additional automation to extend effectivity and accessibility of PacBio’s know-how
The collaboration between PacBio and Novogene is a strategic transfer that strengthens PacBio’s market place in Europe. The Munich lab, outfitted with the Revio long-read sequencing system, enhances Novogene’s capabilities in dealing with advanced and in-depth genomic analysis. This improvement is more likely to enhance PacBio’s market penetration, notably within the uncommon illness and most cancers analysis sectors, the place excessive accuracy and depth of information are vital. The effectivity and scalability launched by the Revio system can place Novogene to draw extra analysis establishments and industrial organizations, thereby boosting demand for PacBio’s applied sciences.
From an funding standpoint, this partnership is poised to drive income development for PacBio by increasing its buyer base and software areas. It demonstrates PacBio’s dedication to advancing genomic analysis and responding to market wants, which may enhance investor confidence and result in a constructive affect on inventory efficiency.
The mixing of PacBio’s Revio long-read sequencing system into Novogene’s Munich lab has important implications for medical analysis, notably in uncommon illness and most cancers research. The high-fidelity and detailed knowledge supplied by the Revio system can uncover advanced genetic variations which can be usually missed by standard short-read sequencing strategies. This functionality is necessary for figuring out novel genetic markers and understanding illness mechanisms at a deeper stage, probably resulting in breakthroughs in prognosis and therapy.
For researchers, this implies elevated entry to high-quality genomic knowledge, which might expedite the invention of recent therapeutic targets and the event of customized medication. This additionally aligns with the rising development in the direction of precision medication, the place therapies are tailor-made primarily based on particular person genetic profiles. The long-term affect could possibly be profound, resulting in simpler therapies and improved affected person outcomes, thereby highlighting the significance of this technological development within the medical analysis area.
The deployment of PacBio’s Revio sequencing system in Novogene’s Munich lab is a technical milestone that underscores the developments in genomic sequencing know-how. The Revio system’s skill to ship extremely correct lengthy reads addresses vital limitations in present sequencing strategies, similar to problem in resolving advanced genomic areas and structural variants. This not solely enhances the depth and high quality of genomic knowledge but additionally makes it less expensive and accessible.
Technologically, this partnership represents a big leap ahead in genomic analysis capabilities, probably influencing the event of recent bioinformatics instruments and knowledge evaluation strategies. By integrating extra automation into the Revio’s workflows, Novogene can streamline the sequencing course of, scale back turnaround instances and scale up its service choices. This technological edge may result in elevated adoption of PacBio’s sequencing options throughout numerous analysis and industrial functions, driving additional innovation within the area.
Extremely correct long-read sequencing knowledge will probably be used at Novogene’s new lab in Munich, supporting prospects throughout a community of main analysis establishments
MENLO PARK, Calif., July 23, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a number one developer of high-quality, extremely correct sequencing options, at present introduced that Novogene is utilizing its Revio long-read sequencing system to increase the capabilities of its new lab in Munich, Germany, serving prospects throughout the European scientific group. Novogene is a number one supplier of genomic companies and bioinformatics experience, working with a variety of main analysis establishments, medical and industrial organizations. The elevated accuracy and throughput supplied by the Revio are designed to allow Novogene’s prospects to scale in-depth genomic analysis throughout uncommon illnesses, most cancers, microbes, and agriculture in an economical means.
“Bringing Revio to our German lab creates new alternatives for our prospects to advance their groundbreaking analysis. We count on notably excessive demand for the Revio from prospects within the uncommon illness and most cancers areas, because of the sequencer’s skill to uncover advanced repetitive areas, structural variants, and novel isoforms which can be usually missed by short-read and exome strategies,” feedback Tingting Zhou, Vice President of Novogene. “The excessive constancy of the Revio, mixed with PacBio’s numerous kits and knowledge evaluation capabilities, make it an excellent resolution to supply our prospects with long-read knowledge in a cost-effective means. We plan to combine much more automation into the Revio’s workflows to additional enhance effectivity and make long-reads accessible to a wider vary of our prospects.”
The brand new lab on the Innovation and Begin-Up Heart for Biotechnology (IZB) in Munich serves as a strategic hub for Novogene’s European operations and builds on its world community of labs throughout the UK, US, Singapore, Japan and China. The addition of the Revio will complement Novogene’s current sequencing portfolio, giving prospects solutions the place different applied sciences have been unable to, resulting from depth or accuracy limitations. In addition to uncommon illness and most cancers analysis, Novogene anticipates excessive demand for the Revio from prospects within the microbial and agrigenomics area, by enabling the de novo meeting of full genomes of hardly ever studied species and the identification of species.
“Novogene’s companies and experience have been supporting pioneering analysis for greater than a decade. Revio’s excessive accuracy means PacBio is properly positioned to be supporting Novogene’s prospects, notably those that are exploring extra advanced organic use instances. We’re happy to be enabling Novogene’s mission of advancing genomics and enhancing life,” feedback Neil Ward, Vice President and Normal Supervisor EMEA, PacBio. “Working with an organization like Novogene that has such a broad buyer base is thrilling for PacBio, as we’ll get to see the Revio getting used for brand spanking new cutting-edge functions. Whether or not that’s advancing human well being or the well being of our planet.”
For extra details about how PacBio is revolutionizing the sector of genomics and to discover the capabilities of the Revio HiFi sequencing system, please go to our web site at https://www.pacb.com/revio/.
Contacts (PacBio)
Buyers:
Todd Friedman
ir@pacificbiosciences.com
Media:
pr@pacificbiosciences.com
About PacBio
PacBio (NASDAQ: PACB) is a premier life science know-how firm that designs, develops, and manufactures superior sequencing options to assist scientists and medical researchers resolve genetically advanced issues. Our merchandise and applied sciences stem from two extremely differentiated core applied sciences targeted on accuracy, high quality and completeness which embody our HiFi long-read sequencing and our SBB® short-read sequencing applied sciences. Our merchandise deal with options throughout a broad set of analysis functions together with human germline sequencing, plant and animal sciences, infectious illness and microbiology, oncology, and different rising functions. For extra data, please go to www.pacb.com and comply with @PacBio.
PacBio merchandise are supplied for Analysis Use Solely. Not to be used in diagnostic procedures.
About Novogene
Novogene is a number one supplier of genomic companies and options with innovative Subsequent Technology Sequencing and bioinformatics experience. With one of many main sequencing capacities on the planet, Novogene utilises scientific excellence, a dedication to customer support and unsurpassed knowledge high quality to assist our shoppers realise their analysis targets within the quickly evolving world of genomics. With virtually 2,000 workers, a number of places world wide, 66 NGS associated patents, and over 22,000 publications in high tier journals similar to Nature and Science, the corporate has turn into a world-leader in NGS companies and a trusted genomics companion. Our companies are supported by the most recent platforms from Illumina, PacBio and Oxford Nanopore Expertise.
Ahead-Wanting Statements
This press launch might comprise “forward-looking statements” throughout the that means of Part 21E of the Securities Trade Act of 1934, as amended, and the U.S. Non-public Securities Litigation Reform Act of 1995. All statements apart from statements of historic truth are forward-looking statements, together with statements regarding the makes use of, protection, benefits, high quality or efficiency of, or advantages or anticipated advantages of utilizing, PacBio merchandise or applied sciences, together with in reference to Novogene’s anticipate use of Revio; and different future occasions. You shouldn’t place undue reliance on forward-looking statements as a result of they’re topic to assumptions, dangers, and uncertainties and will trigger precise outcomes and outcomes to vary materially from presently anticipated outcomes, together with, challenges inherent in sequencing numerous genomes, and the issue of producing discoveries throughout numerous areas of analysis; potential product efficiency and high quality points; third-party claims alleging infringement of patents and proprietary rights or looking for to invalidate PacBio’s patents or proprietary rights; and different dangers related to worldwide operations. Extra elements that would materially have an effect on precise outcomes might be present in PacBio’s most up-to-date filings with the Securities and Trade Fee, together with PacBio’s most up-to-date experiences on Types 8-Okay, 10-Okay, and 10-Q, and embody these listed beneath the caption “Threat Components.” These forward-looking statements are primarily based on present expectations and converse solely as of the date hereof; besides as required by regulation, PacBio disclaims any obligation to revise or replace these forward-looking statements to replicate occasions or circumstances sooner or later, even when new data turns into out there.
FAQ
What’s the objective of Novogene utilizing PacBio’s Revio sequencing system?
Novogene is utilizing PacBio’s Revio long-read sequencing system to increase the capabilities of its new lab in Munich, Germany, enabling prospects to scale genomic analysis throughout uncommon illnesses, most cancers, microbes, and agriculture cost-effectively.
How does the Revio system profit analysis in uncommon illnesses and most cancers?
The Revio system advantages uncommon illness and most cancers analysis by uncovering advanced repetitive areas, structural variants, and novel isoforms which can be usually missed by short-read and exome strategies, offering extra complete genomic knowledge.
What are Novogene’s plans for integrating the Revio system into their workflows?
Novogene plans to combine extra automation into the Revio’s workflows to additional enhance effectivity and make long-read sequencing accessible to a wider vary of their prospects.
Wherein fields does Novogene anticipate excessive demand for PacBio’s Revio system?
Novogene anticipates excessive demand for the Revio system from prospects in uncommon illness and most cancers analysis, in addition to within the microbial and agrigenomics fields.